The review article by Dayyani et al. (1) on novel therapies for metastatic castrateresistant prostate cancer brings much needed attention to the therapeutic implications of interactions between the tumor, stroma, and associated tissue microenvironment in metastatic prostate cancer, an area of considerable importance (2). We were surprised that there was no mention of radium-223, which interacts with an important component of the tumor microenvironment (hydroxyapatite) that is closely intertwined with cancerous cells in osteoblastic bone metastases. This oversight is particularly unfortunate, given that the phase III trial of radium-223 (ClinicalTrials.gov identifier NCT00699751), which enrolled more than 900 patients with bone metastases from castrate-resistant prostate cancer, has recently reported an overall survival benefit (3).
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